Anyone hoping to see Novartis AG enter into any major M&A activity will be disappointed, according to chief financial officer Harry Kirsch who reiterated that bolt-on acquisitions are the priority.
Speaking to journalists as the Swiss major unveiled a decent set of financials for the second quarter which saw sales...